Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial
Strike early–strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
